ScreenerHero

ANTXAN2 Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · an2therapeutics.com
5.810USD-2.52%Mkt Cap: 219.25M $P/E: —

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a on…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap219.25M $
Enterprise Value140.11M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-35.17M $
Revenue/Share—
Last Price5.810 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.24
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.77
EPS (TTM)-1.02
EPS (Forward)-0.80
52W Range
1.00078% of range7.190
52W High7.190 USD
52W Low1.000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-66.29%
ROA-56.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.83M $
CapEx (TTM)—
FCF Margin—
FCF Yield-8.22%
Net Debt-78.39M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio14.32
Quick Ratio14.09
Book Value/Sh2.091 USD
Cash/Share2.077 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.000 USD
Upside (mean)+54.9%
Target Range9.000 USD – 9.000 USD
# Analysts2
Ownership
Shares Out.37.74M
Float21.41M
Insiders18.12%
Institutions75.17%
Short Interest
Short Ratio11.6d
Short % Float7.91%
Short % Out.6.60%
Shares Short2.38M
Short (prev mo.)1.92M
Technical
SMA 505.123 (+13.4%)
SMA 2003.130 (+85.6%)
Beta-0.99
S&P 52W Chg18.16%
Avg Vol (30d)214.00K
Avg Vol (10d)216.13K
Technical Indicators
RSI (14)56.8
MACD0.2843
MACD Signal0.3010
MACD Hist.-0.0167
BB Upper6.553 USD
BB Middle5.604 USD
BB Lower4.654 USD
BB Width33.91%
ATR (14)0.4451 USD
Vol Ratio (20d)1.11x